Application of Medicare's New Technology Add-on Payment Program for Blinatumomab

JAMA Oncol. 2016 Feb;2(2):165-6. doi: 10.1001/jamaoncol.2015.5359.

Authors

Sanket S Dhruva¹, Vinay Prasad²

Affiliations

¹ Robert Wood Johnson Foundation Clinical Scholars Program, Yale University School of Medicine, New Haven, Connecticut2Department of Internal Medicine, Connecticut Veterans Affairs Health System, West Haven, Connecticut.
² Division of Hematology-Oncology, Knight Cancer Institute, Department of Public Health and Preventive Medicine, Oregon Health and Sciences University, Portland.

PMID: 26720844
DOI: 10.1001/jamaoncol.2015.5359

No abstract available

MeSH terms

Antibodies, Bispecific / administration & dosage
Antibodies, Bispecific / economics*
Antibodies, Bispecific / therapeutic use*
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / economics*
Antineoplastic Agents / therapeutic use*
Cost-Benefit Analysis
Drug Administration Schedule
Drug Costs* / legislation & jurisprudence
Health Services Accessibility / economics
Humans
Infusions, Intravenous
Insurance, Health, Reimbursement / economics*
Insurance, Health, Reimbursement / legislation & jurisprudence
Medicare / economics*
Medicare / legislation & jurisprudence
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / economics*
Time Factors
Treatment Outcome
United States

Substances

Antibodies, Bispecific
Antineoplastic Agents
blinatumomab